Drug survival of adalimumab, secukinumab, and ustekinumab in psoriasis as determined by either dose escalation or drug discontinuation during the first 3 years of treatment - a nationwide cohort study.

[1]  L. Skov,et al.  Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis - a nationwide cohort study. , 2023, Journal of the American Academy of Dermatology.

[2]  C. Griffiths,et al.  Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis. , 2022, JAMA dermatology.

[3]  Y. Lytvyn,et al.  Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study , 2021, JAAD international.

[4]  L. Teixeira,et al.  Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study , 2021, American Journal of Clinical Dermatology.

[5]  B. Strober,et al.  Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry , 2021, Dermatologic therapy.

[6]  R. Gniadecki,et al.  Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis , 2020, Frontiers in Medicine.

[7]  C. Griffiths,et al.  Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) , 2020, The British journal of dermatology.

[8]  C. Peralta,et al.  Real‐world evidence of secukinumab in psoriasis treatment – a meta‐analysis of 43 studies , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  L. Skov,et al.  Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. , 2019, Journal of the American Academy of Dermatology.

[10]  M. Zorko,et al.  Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis , 2019, International journal of dermatology.

[11]  M. Megna,et al.  Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. , 2019, Journal of the American Academy of Dermatology.

[12]  C. Chi,et al.  Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence , 2018, Scientific Reports.

[13]  L. Skov,et al.  Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis , 2018, The British journal of dermatology.

[14]  N. Reynolds,et al.  Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) , 2017, The Journal of investigative dermatology.

[15]  M. Sundaram,et al.  Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study , 2017, The Journal of dermatological treatment.

[16]  A. Kimball,et al.  Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double‐blinded, placebo‐ and active comparator–controlled VOYAGE 1 trial , 2017, Journal of the American Academy of Dermatology.

[17]  A. Burden,et al.  Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). , 2015, The Journal of investigative dermatology.

[18]  Yang Zhao,et al.  Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. , 2015, Journal of managed care & specialty pharmacy.

[19]  L. Skov,et al.  Comparison of long‐term drug survival and safety of biologic agents in patients with psoriasis vulgaris , 2015, The British journal of dermatology.

[20]  P. C. van de Kerkhof,et al.  Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice , 2013, The Journal of dermatological treatment.

[21]  A. Armstrong,et al.  Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy , 2012, PloS one.